Biology:Serum amyloid P component

From HandWiki
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example


The serum amyloid P component (SAP) is the identical serum form of the amyloid P component (AP), a 25 kDa pentameric protein first identified as the pentagonal constituent of in vivo pathological deposits called "amyloid".[1] APCS is its human gene.[2]

In amyloidosis

SAP makes up 14% of the dry mass of amyloid deposits[3] and is thought to be an important contributor to the pathogenesis of a related group of diseases called the Amyloidoses.[4] These conditions are characterised by the ordered aggregation of normal globular proteins and peptides into insoluble fibres, which disrupt tissue architecture and are associated with cell death. SAP is thought to decorate and stabilise aggregates by preventing proteolytic cleavage and hence inhibiting fibril removal via the normal protein scavenging mechanisms.[5] This association is utilised in the routine clinical diagnostic technique of SAP scintigraphy whereby radio-labelled protein is injected into patients to locate areas of amyloid deposition.[6] The SAP-amyloid association has also been identified as a possible drug target for anti-amyloid therapy, with the recent development and first stage clinical trials of a compound called CPHPC (R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxohexanoyl] pyrrolidine-2-carboxylic acid), a small molecule able to strip AP from deposits by reducing levels of circulating SAP.[7]

Structure

SAP is a member of the pentraxins family, characterised by calcium-dependent ligand binding and a distinctive flattened β-jellyroll structure similar to that of the legume lectins.[8] The name "pentraxin" is derived from the Greek words for five (penta) and berries (ragos), relating to the radial symmetry of five monomers forming a ring approximately 95 across and 35 deep. Human SAP has 51% sequence homology with C-reactive protein (CRP), a classical acute phase response plasma protein, and is a more distant relative to the "long" pentraxins such as PTX3 (a cytokine-modulated molecule) and several neuronal pentraxins. Both SAP and CRP are evolutionary conserved in all vertebrates and are also found in distant invertebrates such as the horseshoe crab (Limulus polyphemus).[9]

References

  1. Cathcart ES; Shirahama T; Cohen AS (1967). "Isolation and identification of a plasma component of amyloid". Biochim. Biophys. Acta 147 (2): 392–393. doi:10.1016/0005-2795(67)90420-5. 
  2. "Entrez Gene: APCS amyloid P component, serum". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=325. 
  3. Skinner M; Pepys MB; Cohen AS; Heller LM; Lian JB (1980). Amyloid and amyloidosis: proceedings of the Third International Symposium on Amyloidosis, Póvoa de Varzim, Portugal, 23–28 September 1979. Amsterdam: Excerpta Medica. pp. 384–391. ISBN 0-444-90124-8. 
  4. "Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene". Nature Medicine 3 (8): 855–9. August 1997. doi:10.1038/9544. PMID 9256275. 
  5. "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis". Proceedings of the National Academy of Sciences of the United States of America 92 (10): 4299–303. May 1995. doi:10.1073/pnas.92.10.4299. PMID 7753801. PMC 41931. http://www.pnas.org/cgi/reprint/92/10/4299.pdf. 
  6. "Imaging amyloidosis with radiolabelled SAP". European Journal of Nuclear Medicine 22 (7): 595–9. July 1995. doi:10.1007/BF01254559. PMID 7498219. 
  7. "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis". Nature 417 (6886): 254–9. May 2002. doi:10.1038/417254a. PMID 12015594. 
  8. "Structure of pentameric human serum amyloid P component". Nature 367 (6461): 338–45. January 1994. doi:10.1038/367338a0. PMID 8114934. 
  9. "Amyloid P component. A critical review". Amyloid 4 (4): 274–295. 1997. doi:10.3109/13506129709003838.